Evidence mapPaperPMID 27769710Full record

ArticleDNA repair2016

Elevated urinary levels of 8-oxo-2'-deoxyguanosine, (5'R)- and (5'S)-8,5'-cyclo-2'-deoxyadenosines, and 8-iso-prostaglandin F

Melis Kant, Merve Akış, Mehmet Çalan, Tuğba Arkan, Fırat Bayraktar, Miral Dizdaroglu, Hüray İşlekel

Open access · greenAbstract read
In one paragraph

Article in DNA repair, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 46 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Renal and cerebral RAS interaction contributes to diabetic kidney disease.American journal of translational research · 2019
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Melis KantDepartment of Medical Biochemistry, Institute of Health Sciences, School of Medicine, Dokuz Eylul University, 35340, Izmir, Turkey. Electronic address: melissdinc@gmail.com.
Merve AkışDepartment of Medical Biochemistry, Institute of Health Sciences, School of Medicine, Dokuz Eylul University, 35340, Izmir, Turkey.
Mehmet ÇalanDivision of Endocrinology, Izmir Bozkaya Research and Education Hospital, 35170, Izmir, Turkey.
Tuğba ArkanDivision of Endocrinology, Derince Research and Education Hospital, 41900, Kocaeli, Turkey.
Fırat BayraktarDepartment of Internal Medicine, Division of Endocrinology and Metabolism, School of Medicine, Dokuz Eylul University, 35340, Izmir, Turkey.
Miral DizdarogluBiomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA.
Hüray İşlekelDepartment of Medical Biochemistry, Institute of Health Sciences, School of Medicine, Dokuz Eylul University, 35340, Izmir, Turkey; Department of Molecular Medicine, Institute of Health Sciences, School of Medicine, Dokuz Eylul University, 35340, Izmir, Turkey.
Dokuz Eylül University · TRIzmir Bozyaka Eğitim ve Araştırma Hastanesi · TRNational Institute of Standards and Technology · US

Funding

Intramural NIST DOC 9999-NIST
6 · The paper itself

Abstract

Prediabetes is the preclinical stage of type 2 diabetes mellitus (T2DM) with intermediate state of hyperglycemia. Hyperglycemia results in a state of oxidative stress, which may contribute to the production of insulin resistance, β-cell dysfunction and long-term complications of diabetes. Novel approaches are required for prevention and treatment of diabetes. New biomarkers that can be used in risk stratification and therapy control as supplementary to current parameters are needed. These biomarkers may facilitate a more individualized and sufficient treatment of diabetes. Therefore, the aim of this study was to investigate the levels of oxidatively induced DNA damage products, 8-oxo-2'-deoxyguanosine (8-oxo-dG) (also known as 8-OH-dG), (5'R)- and (5'S)-8,5'-cyclo-2'-deoxyadenosines (R-cdA and S-cdA), and the lipid peroxidation product 8-iso-prostaglandin F

Indexed as

Oxidative Stress8-Hydroxy-2'-DeoxyguanosineAdultAgedBiomarkersCase-Control StudiesCholesterol, HDLCholesterol, LDLChromatography, LiquidC-Reactive ProteinDeoxyadenosinesDeoxyguanosineDiabetes Mellitus, Type 2DinoprostDNA DamageFemale8,5'-cyclo-2'-deoxyadenosine8-epi-prostaglandin F2alpha8-Hydroxy-2'-DeoxyguanosineBiomarkersCholesterol, HDLCholesterol, LDLC-Reactive ProteinDeoxyadenosinesDeoxyguanosineDinoprostGlycated Hemoglobinhemoglobin A1c protein, humanTriglycerides8,5′-cyclo-2′-Deoxyadenosines8-iso-Prostaglandin F(2α)8-Oxo-2′-deoxyguanosineLipid peroxidationOxidatively induced DNA damagePrediabetes

Identifiers

PMID27769710
PMCPMC11274812
OpenAlexW2525818585

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.